Swaminathan Padmanabhan Iyer, MD

Associate Professor of Medicine, Institute for Academic Medicine
Houston Methodist
Weill Cornell Medical College


Dr. Iyer is a Hematologist/Oncologist and has extensive expertise in early phase clinical studies including several first in human anticancer agents; he was part of pivotal studies that led to the FDA approval of the new anti-CD20 monoclonal antibody Ofatumumab or Arzerra in Chronic Lymphocytic Leukemia and the Histone Deacetylase inhibitor Romidepsin or Istodax in Peripheral T cell Lymphomas. Dr. Iyer has won numerous awards including Outstanding Volunteer Physician for 2010 by the Leukemia Lymphoma Society and has been listed as one of America’s Top Physicians since 2007.

Dr. Iyer received his MB, BS, from Bangalore Medical College, India. He completed his internship and residency in medicine at Wayne State University; and Fellowship in Hematology/Medical Oncology at the Sylvester Comprehensive Cancer Center, University of Miami, Florida. Soon after his fellowship, he spent many years at the Roswell Park Cancer Institute as the staff physician in Lymphoma at the Myeloma Care Center and participated in the Blood and Marrow Transplant Program. He then worked as the Director of Hematological Malignancies at the Cancer Therapy & Research Center, UTHSC, San Antonio before moving to Houston Methodist.

Dr. Iyer is a Diplomat of the American Board of Internal Medicine and is board certified in Internal Medicine, Hematology and Medical Oncology. He is currently the Leader of the Early Drug Development Program in Oncology and Hematology, and Co-Director of the Malignant Hematology Program. Dr. Iyer has extensive expertise in early phase clinical studies including several first in human anticancer agents.

Areas Of Expertise

Leukemia Malignant Hematology Early Drug Development Lymphoma

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Pro, B, Horwitz, SM, Prince, HM, Foss, FM, Sokol, L, Greenwood, M, Caballero, D, Morschhauser, F, Wilhelm, M, Iyer, SP, Shustov, AR, Wolfson, J, Balser, BE & Coiffier, B 2016, Hematological Oncology. DOI:

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy
Jewell, RC, Kipps, TJ, Dürig, J, Griskevicius, L, Stilgenbauer, S, Smolej, L, Mayer, J, Hess, G, Hernandez-Ilizaliturri, FJ, Padmanabhan-Iyer, S, Fang, L, Goldstein, N, Gorczyca, M, Gupta, I, Lisby, S & Wierda, WG 2016, Leukemia and Lymphoma, pp. 1-9. DOI:

Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China
Lu, J, Hou, J, Liu, KY, Parmar, S, De La Fuente, A, Andersson, B, Yan, C, Zhou, D, Tan, D, Ritchie, D, Wu, D, Shpall, E, Laport, GG, Li, J, Hu, J, Zhang, LS, Wang, M, Malhotra, P, Jiang, Q, Qin, Y, Wong, R, Champlin, R, Issaragrisil, S, Iyer, S, Mathews, V, Wang, Y, Hu, Y, Xiao, Z, Shao, Z, Rosengarten, R, Steuernagle, J, Xiao, JH, Orlowski, R & Chim, JCS 2016, Leukemia and Lymphoma, pp. 1-5. DOI:

Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M, Kelly, KR, Yee, K, Assouline, S, Strair, R, Popplewell, L, Bowen, D, Martinelli, G, Drummond, MW, Vyas, P, Kirschbaum, M, Iyer, SP, Ruvolo, V, Gonzalez, GMN, Huang, X, Chen, G, Graves, B, Blotner, S, Bridge, P, Jukofsky, L, Middleton, S, Reckner, M, Rueger, R, Zhi, J, Nichols, G & Kojima, K 2016, Clinical Cancer Research, vol 22, no. 4, pp. 868-876. DOI:

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
Devaraj, SGT, Fiskus, W, Shah, B, Qi, J, Sun, B, Iyer, SP, Sharma, S, Bradner, JE & Bhalla, KN 2016, Leukemia, vol 30, no. 2, pp. 504-508. DOI:

Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study
Sehn, LH, Goy, A, Offner, FC, Martinelli, G, Caballero, MD, Gadeberg, O, Baetz, T, Zelenetz, AD, Gaidano, G, Fayad, LE, Buckstein, R, Friedberg, JW, Crump, M, Jaksic, B, Zinzani, PL, Iyer, SP, Sahin, D, Chai, A, Fingerle-Rowson, G & Press, OW 2015, Journal of Clinical Oncology, vol 33, no. 30, pp. 3467-3474. DOI:

Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia
Zhao, N, Pei, SN, Qi, J, Zeng, Z, Iyer, SP, Lin, P, Tung, CH & Zu, Y 2015, Biomaterials, vol 67, pp. 42-51. DOI:

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: Final results from a pivotal study
Österborg, A, Jewell, RC, Padmanabhan-Iyer, S, Kipps, TJ, Mayer, J, Stilgenbauer, S, Williams, CD, Hellmann, A, Furman, RR, Robak, T, Hillmen, P, Trnêný, M, Dyer, MJS, Piotrowska, M, Kozak, T, Gupta, IV, Phillips, JL, Goldstein, N, Struemper, H, Losic, N, Lisby, S & Wierda, WG 2015, Haematologica, vol 100, no. 8. DOI:

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
Wen, J, Tao, W, Hao, S, Iyer, SP & Zu, Y 2016, Leukemia, vol 30, no. 4, pp. 987-91. DOI:

Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
Seggewiss-Bernhardt, R, Bargou, RC, Goh, YT, Stewart, AK, Spencer, A, Alegre, A, Bladé, J, Ottmann, OG, Fernandez-Ibarra, C, Lu, H, Pain, S, Akimov, M & Iyer, SP 2015, Cancer, vol 121, no. 13, pp. 2185-2192. DOI:

Romidepsin for the treatment of peripheral t-cell lymphoma
Iyer, SP & Foss, FF 2015, Oncologist, vol 20, no. 9, pp. 1084-1091. DOI:

Pre-clinical efficacy of combined therapy with novel ß-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
Fiskus, W, Sharma, S, Saha, S, Shah, B, Devaraj, SGT, Sun, B, Horrigan, S, Leveque, C, Zu, Y, Iyer, S & Bhalla, KN 2015, Leukemia, vol 29, no. 6, pp. 1267-1278. DOI:

Utility of <sup>18</sup>fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
Horwitz, S, Coiffier, B, Foss, F, Prince, HM, Sokol, L, Greenwood, M, Caballero, D, Morschhauser, F, Pinter-Brown, L, Iyer, SP, Shustov, A, Nichols, J, Balser, J, Balser, B & Pro, B 2015, Annals of Oncology, vol 26, no. 4, pp. 774-779. DOI:

Erratum: WTAP is a novel oncogenic protein in acute myeloid leukemia (Leukemia (2014) 28 (1171-1174) DOI: 10.1038/leu.2014.16)
Bansal, H, Yihua, Q, Iyer, SP, Ganapathy, S, Proia, DA, Penalva, LO, Uren, PJ, Suresh, U, Carew, JS, Karnad, AB, Weitman, S, Tomlinson, GE, Rao, MK, Kornblau, SM & Bansal, S 2014, Leukemia, vol 28, no. 12, pp. 2427. DOI:

BET protein antagonist JQ1 is synergistically lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD
Fiskus, W, Sharma, S, Qi, J, Shah, B, Devaraj, SGT, Leveque, C, Portier, BP, Iyer, S, Bradner, JE & Bhalla, KN 2014, Molecular Cancer Therapeutics, vol 13, no. 10, pp. 2315-2327. DOI:

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
Fiskus, W, Sharma, S, Shah, B, Portier, BP, Devaraj, SGT, Liu, K, Iyer, SP, Bearss, D & Bhalla, KN 2014, Leukemia. DOI:

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
Coiffier, B, Pro, B, Prince, HM, Foss, F, Sokol, L, Greenwood, M, Caballero, D, Morschhauser, F, Wilhelm, M, Pinter-Brown, L, Padmanabhan Iyer, S, Shustov, A, Nielsen, T, Nichols, J, Wolfson, J, Balser, B & Horwitz, S 2014, Journal of Hematology and Oncology, vol 7, no. 1, 11. DOI:

A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events
Iyer, SP, Beck, JT, Stewart, AK, Shah, J, Kelly, KR, Isaacs, R, Bilic, S, Sen, S & Munshi, NC 2014, British Journal of Haematology, vol 167, no. 3, pp. 366-375. DOI:

Phase I study of MLN8237 - Investigational Aurora A kinase inhibitor - In relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia
Kelly, KR, Shea, TC, Goy, A, Berdeja, JG, Reeder, CB, McDonagh, KT, Zhou, X, Danaee, H, Liu, H, Ecsedy, JA, Niu, H, Benaim, E & Padmanabhan Iyer, S 2014, Investigational New Drugs, vol 32, no. 3, pp. 489-499. DOI:

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells
Fiskus, W, Sharma, S, Qi, J, Valenta, JA, Schaub, LJ, Shah, B, Peth, K, Portier, BP, Rodriguez, M, Devaraj, SGT, Zhan, M, Sheng, J, Iyer, SP, Bradner, JE & Bhalla, KN 2014, Molecular Cancer Therapeutics, vol 13, no. 5, pp. 1142-1154. DOI: